Arthritis News and Research

Latest Arthritis News and Research

Rigel Pharmaceuticals, AstraZeneca license agreement: Waiting period under Antitrust Improvements Act expires

Rigel Pharmaceuticals, Inc. today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 relating to the license agreement between Rigel and AstraZeneca, the effectiveness of which was contingent on the expiration of the waiting period.

29 Mar 2010

Norovirus outbreak associated with oysters: FDA and Mississippi, Louisiana public health agencies issue warning

The U.S. Food and Drug Administration is working with state health officials from Mississippi and Louisiana to notify consumers, food service operators and retailers nationwide about an outbreak of norovirus associated with oysters recently harvested from an area near Port Sulphur, La. known as Area 7. The oysters were sold or distributed nationwide.

27 Mar 2010

Lung transplant patients may one day benefit from synthetic peptide, researchers report

Lung transplant patients may one day benefit from a synthetic peptide that mimics the body's natural ability to reduce excess fluid accumulation, Medical College of Georgia researchers report.

26 Mar 2010

NYU researchers identify novel therapy for rheumatoid arthritis

By enhancing the activity of immune cells that protect against runaway inflammation, researchers at NYU Langone Medical Center may have found a novel therapy for rheumatoid arthritis and other autoimmune diseases.

26 Mar 2010

EVMS researchers awarded $1,076,250 grant to develop functional cure for Type 1 diabetes

Researchers at the Eastern Virginia Medical School Strelitz Diabetes Center have been awarded a $1,076,250 grant by the Department of Defense Peer Reviewed Medical Research Program to develop new ways of reversing the underlying causes of Type 1 diabetes.

26 Mar 2010

VisEn Medical announces launch of new GastroSense 750 fluorescence agent for imaging gastric motility

VisEn Medical Inc., a leader in fluorescence imaging from research through medicine, announced today the commercial launch of its new GastroSense™ 750 fluorescence agent for imaging gastric motility and related drug effects in vivo.

26 Mar 2010

Flip-flops and sneakers may help reduce osteoarthritis

Flip-flops and sneakers with flexible soles are easier on the knees than clogs or even special walking shoes, a study by Rush University Medical Center has found. And that's important, because loading on the knee joints is a key factor in the development of osteoarthritis.

25 Mar 2010

ScinoPharm announces record results for fiscal year 2009

ScinoPharm, an active pharmaceutical ingredient specialist, today announced audited record results for its fiscal year 2009. The company posted NT$3.791 billion in revenue, an increase of 20.54% over 2008.

25 Mar 2010

Biogen Idec and Elan begin comparative trial of MS treatments

Biogen Idec and Elan Corporation, plc (NYSE: ELN) today announced enrollment of the first patient in a global Phase IIIb, randomized, rater-blinded, active-controlled study designed to evaluate switching to TYSABRI® (natalizumab) from Copaxone® (glatiramer acetate) or Rebif® (interferon beta-1a) in patients with relapsing remitting multiple sclerosis.

25 Mar 2010

Research could pave way for new generation of painkillers

An international group of scientists led by Dr Nikita Gamper of the University's Faculty of Biological Sciences has discovered how two proteins play a key role in the way we feel pain, offering new targets on which drug development can be focused.

25 Mar 2010

NIH grant for study on impact of gastric bypass surgery on Type II diabetes patients

Gastric bypass surgery, thought of by many as the last hope of morbidly obese people for losing weight, has many other benefits researchers are only beginning to understand.

25 Mar 2010

Patients to discuss future of health care system at Canadian Patient Summit

More than 100 patients living with chronic medical conditions will share their solutions for ensuring that patients are part of government decisions on the future of Canada's health care system.

24 Mar 2010

Portola Pharmaceuticals commences Phase 1 trial of PRT062607 for chronic inflammatory diseases

Portola Pharmaceuticals, Inc. today announced that it has initiated its first in human Phase 1 trial in healthy volunteers of PRT062607, a novel, oral Syk-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis (RA), and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In preclinical in vivo models of RA, PRT062607 was shown to reduce inflammation in a dose-dependent manner.

23 Mar 2010

ReGear Life Sciences achieves preferred partner status with Genesis Rehab Services

ReGear Life Sciences, Inc. announces that it has been named a Preferred Partner to Genesis Rehab Services.

23 Mar 2010

Walgreens's fiscal 2010 second-quarter sales up 3.1% to $17.0 billion

Walgreens today announced earnings and sales for the second quarter of fiscal year 2010.

23 Mar 2010

Dual-energy CT helps diagnose gout reliably in acute, emergency settings

A medical imaging technique called dual-energy computed tomography (CT) is an effective and reliable way to diagnose gout in the acute, emergency setting, according to a study published in the April issue of the American Journal of Roentgenology. Dual-energy CT is an advanced medical imaging technique that can detect vessels and bones and display them in clear contrast to one another. It enables physicians to diagnose many patients' conditions faster and more accurately as it can better characterize tissue composition better than conventional CT.

23 Mar 2010

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

Can-Fite BioPharma Ltd, a biopharmaceutical company, traded on the TASE and developing anti- inflammatory and anti-cancer drugs, announced today the filing of a patent application, in conjunction with the United Stated National Institutes of Health (NIH), for the treatment of Uveitis with its A3 adenosine receptor ligands.

23 Mar 2010

ChemoCentryx undertakes Phase II clinical trial of CCX140

ChemoCentryx, Inc., today announced that it has undertaken a Phase II clinical trial of CCX140, a novel, orally-available small molecule compound designed to specifically target the chemokine receptor known as CCR2.

22 Mar 2010

AARDA launches campaign on family AQ

In honor of the designation of March as National Autoimmune Disease Awareness Month by the U.S. Senate on March 4, 2010, the American Autoimmune Related Diseases Association (AARDA) wants to help you learn your family's AQ. AQ is a play on IQ that stands for Autoimmune Quotient. It's about knowing how likely you or a loved one is to develop an autoimmune disease, based on the prevalence of these diseases and your family history. The campaign features AARDA National Spokesperson and Actress Kellie Martin, best known for her memorable roles on "E.R." and "Life Goes On."

22 Mar 2010

Portable ultrasound device to treat chronic joint pain from arthritis

In recent years, doctors have used ultrasound to effective treat joint pain from arthritis and other ailments without the use of drugs. The drawback to these treatments, however, is that they can only be administered in a doctor's office or clinic, since the ultrasound devices currently used are bulky and expensive.

20 Mar 2010

Arthritis News and Research

Latest Arthritis News and Research

Rigel Pharmaceuticals, AstraZeneca license agreement: Waiting period under Antitrust Improvements Act expires

Norovirus outbreak associated with oysters: FDA and Mississippi, Louisiana public health agencies issue warning

Lung transplant patients may one day benefit from synthetic peptide, researchers report

NYU researchers identify novel therapy for rheumatoid arthritis

EVMS researchers awarded $1,076,250 grant to develop functional cure for Type 1 diabetes

VisEn Medical announces launch of new GastroSense 750 fluorescence agent for imaging gastric motility

Flip-flops and sneakers may help reduce osteoarthritis

ScinoPharm announces record results for fiscal year 2009

Biogen Idec and Elan begin comparative trial of MS treatments

Research could pave way for new generation of painkillers

NIH grant for study on impact of gastric bypass surgery on Type II diabetes patients

Patients to discuss future of health care system at Canadian Patient Summit

Portola Pharmaceuticals commences Phase 1 trial of PRT062607 for chronic inflammatory diseases

ReGear Life Sciences achieves preferred partner status with Genesis Rehab Services

Walgreens's fiscal 2010 second-quarter sales up 3.1% to $17.0 billion

Dual-energy CT helps diagnose gout reliably in acute, emergency settings

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

ChemoCentryx undertakes Phase II clinical trial of CCX140

AARDA launches campaign on family AQ

Portable ultrasound device to treat chronic joint pain from arthritis

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Arthritis News and Research

Latest Arthritis News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in